At close: December 13 at 4:00:01 PM EST
After hours: 7:58:23 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
48,214.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
Operating Income
-48,214.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
Net Non Operating Interest Income Expense
3,889.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
Other Income Expense
-20.0000
469.0000
142.0000
-293.0000
-9.0000
Pretax Income
-44,345.0000
-29,097.0000
-29,188.0000
-33,961.0000
-32,776.0000
Tax Provision
-28.0000
-32.0000
-36.0000
-21.0000
-18.0000
Net Income Common Stockholders
-44,317.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Diluted NI Available to Com Stockholders
-44,317.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Basic EPS
-0.44
-0.29
-0.45
-1.49
-1.77
Diluted EPS
-0.44
-0.29
-0.45
-1.49
-1.77
Basic Average Shares
100,334.7950
99,033.3730
64,541.9110
22,841.4810
18,546.7860
Diluted Average Shares
100,334.7950
99,033.3730
64,541.9110
22,841.4810
18,546.7860
Total Operating Income as Reported
-48,214.0000
-33,923.0000
-29,907.0000
-32,476.0000
-32,489.0000
Total Expenses
48,214.0000
33,923.0000
29,907.0000
32,476.0000
32,489.0000
Net Income from Continuing & Discontinued Operation
-44,317.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Normalized Income
-44,317.0000
-29,065.0000
-29,005.1470
-34,021.9180
-32,749.0090
Interest Income
3,896.0000
4,748.0000
1,740.0000
10.0000
178.0000
Interest Expense
7.0000
391.0000
1,163.0000
1,202.0000
456.0000
Net Interest Income
3,889.0000
4,357.0000
577.0000
-1,192.0000
-278.0000
EBIT
-44,338.0000
-28,706.0000
-28,025.0000
-32,759.0000
-32,320.0000
EBITDA
-44,194.0000
-28,583.0000
-27,982.0000
-32,709.0000
-32,273.0000
Reconciled Depreciation
144.0000
123.0000
43.0000
50.0000
47.0000
Net Income from Continuing Operation Net Minority Interest
-44,317.0000
-29,065.0000
-29,152.0000
-33,940.0000
-32,758.0000
Total Unusual Items Excluding Goodwill
-94.0000
--
-147.0000
82.0000
-9.0000
Total Unusual Items
-94.0000
--
-147.0000
82.0000
-9.0000
Normalized EBITDA
-44,194.0000
-28,583.0000
-27,835.0000
-32,791.0000
-32,264.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
--
--
-0.1470
0.0820
-0.0090
12/31/2020 - 5/7/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PALI Palisade Bio, Inc.
1.7700
-25.00%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.8100
+2.26%
PBM Psyence Biomedical Ltd.
1.8500
-9.31%
CRDF Cardiff Oncology, Inc.
3.9200
+19.88%
CMRX Chimerix, Inc.
2.9500
+0.34%
PCSA Processa Pharmaceuticals, Inc.
1.1100
-11.20%
TARA Protara Therapeutics, Inc.
5.98
-4.32%
APVO Aptevo Therapeutics Inc.
4.0900
-27.35%
DBVT DBV Technologies S.A.
3.5700
-7.03%
SLXN Silexion Therapeutics Corp
3.5200
+5.39%